Lv1
76 积分 2024-10-27 加入
Efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapies
2个月前
已完结
Epcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results from the EPCORE NHL-2 trial
2个月前
已完结
Results of a Second, Prespecified Analysis of the Phase 2 Study ELM-2 Confirm High Rates of Durable Complete Response with Odronextamab in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) with Extended Follow-up
3个月前
已完结
Glofitamab in refractory or relapsed diffuse large B cell lymphoma after failing CAR-T cell therapy: a phase 2 LYSA study
3个月前
已完结
Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study
3个月前
已完结
Comparison of CAR T-cell vs. bispecific antibody as third- or later-line large Bcell lymphoma therapy: A Meta-analysis
3个月前
已关闭
Comparison of CAR T-cell vs. bispecific antibody as third- or later-line large Bcell lymphoma therapy: A Meta-analysis
3个月前
已关闭
Non-relapse mortality with bispecific antibodies: A systematic review and meta-analysis in lymphoma and multiple myeloma
4个月前
已完结
Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial
4个月前
已完结
Preparation of AgBiS2 thin films with vapor-assisted solution method for flexible near-infrared photodetectors
3个月前
已采纳
A phase III clinical trial of GC1111 as an enzyme replacement therapy in previously untreated mucopolysaccharidosis type II (Hunter syndrome) patients: A double-blind, randomized, active-controlled (part 1) and open-labeled, historical placebo-controlled (part 2) study
3个月前
已采纳
皖公网安备34019202002308
